Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results
02 nov. 2017 16h00 HE
|
Arbutus Biopharma Corporation
Strategic Investment from Roivant Extends Cash RunwayCombination Study for ARB-1467 Starting in 4Q17Company to Host a Corporate Update Conference Call Today at 4:15 PM ET VANCOUVER, British Columbia...
Arbutus Announces Conference Call to Provide a Corporate Update and Third Quarter 2017 Financial Results
31 oct. 2017 18h16 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Presents HBV Data at 2017 AASLD Liver Meeting
24 oct. 2017 08h00 HE
|
Arbutus Biopharma Corporation
Phase 2 ARB-1467 Combination Study Starting in 4Q17Expected IND-filings in 2018 for Two New Oral Compounds VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Arbutus...
M2 Compliance® to Sponsor the 3rd Annual Dawson James Small Cap Growth Conference
19 oct. 2017 09h14 HE
|
M2 Compliance
Los Angeles, Oct. 19, 2017 (GLOBE NEWSWIRE) -- M2 Compliance® ("M2"), www.m2compliance.com, a world-leading filing agent registered with the Securities and Exchange Commission and full-service...
Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients
18 oct. 2017 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa. and EMERYVILLE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV)...
Arbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences
16 oct. 2017 10h30 HE
|
Arbutus Biopharma Corporation; Roivant Sciences Ltd.
VANCOUVER, British Columbia and WARMINSTER, Pa. , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions...
Arbutus to Participate in Upcoming Investor Conferences
10 oct. 2017 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
M2 Compliance to Sponsor the MicroCap Conference
05 oct. 2017 09h53 HE
|
M2 Compliance
New York,, Oct. 05, 2017 (GLOBE NEWSWIRE) -- M2 Compliance® ("M2"), www.m2compliance.com, a world-leading filing agent registered with the Securities and Exchange Commission and full-service...
Arbutus to Present HBV Data at 2017 AASLD Liver Meeting
03 oct. 2017 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions...
Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences
02 oct. 2017 07h00 HE
|
Arbutus Biopharma Corporation
Cash to Provide Significant Support for Arbutus to Fund HBV R&D PipelineRoivant to Support Accelerating Development of Arbutus’ HBV Pipeline and Maximizing the Value of Arbutus’ LNP Assets ...